Cardio-Renal Check-up - DiaPat® KardiOM RenOM Test
Heart and kidneys are directly interrelated. Consequently, a disease of one organ interferes with the other organ. This is called "cardio-renal syndrome".
The DiaPat® KardiOM RenOM Test test is based on the innovative diagnostic approach of urinary proteome analysis allowing an early and reliable detection of coronary artery disease and chronic kidney disease as well as differential diagnosis of chronic kidney disease. The test enables differentiation between the following kidney diseases: Minimal Change Disease (MCD), Membranous Glomerulonephritis (MNGN), Focal Segmental Glomerulosclerosis (FSGS), Lupus Nephritis (SLE), Immunoglobulin-A-Nephropathy (IgA-Nephropathy), Vascular Nephropathy and Diabetic Nephropathy.
The DiaPat®-CR test in combination with early therapeutic intervention is capable to prevent progression of coronary artery disease and renal damage and therefore significantly improves the clinical prognosis.
Coronary Artery Disease - DiaPat® KardiOM Test
Coronary artery disease (CAD) is one of the major causes of death worldwide causing almost every second death. Most preventive health check-ups however, are not sensitive for early alterations or are associated with invasive or radiant procedures. The DiaPat® KardiOM Test analyses the urine proteome and allows an accurate and non-invasive detection of coronary artery disease, even before symptoms occur.
Primarily patients, who display no clear symptoms, but also all patients carrying increased risks, such as for example diabetes patients, smokers and overweight individuals can benefit from it. Early diagnosis facilitates early treatment or a change of habits (diet, physical activity, giving up smoking).
The DiaPat® KardiOM Test is also able to detect heart failure (systolic and diastolic) as well as the risk of heart attacks up to eight years in advance.
Chronic Nephropathies - DiaPat® RenOM Test
Diagnosis of chronic kidney disease is established at a late stage, when substantial organ damage occurred. The analysis of the urine proteome through the DiaPat® RenOM Test enables detecting chronic kidney diseases (CKD) at a very early stage with an accuracy of approximately 94%.
Diabetic Nephropathy - DiaPat® DN-PROteom Test
Diabetic nephropathy (DN) is a chronic kidney disease that develops as a result of diabetes mellitus. DN is often characterized by a slow, progressive loss of renal function, with a loss of glomerular filtration over a period of months or years that eventually leads to end-stage renal disease requiring renal replacement therapy (dialysis or kidney transplantation). About 25% to 40% of the patients with diabetes will develop diabetic nephropathy.
Diabetic nephropathy is generally detected by measurements of albumin in urine or changes in serum creatinine concentration in blood. However, these methods are late manifestations of renal damage.
Analysing the urine proteome, the DiaPat® DN-PROteom Test allows the detection of diabetic nephropathy 3-5 years prior to the occurrence of clinical symptoms. An accuracy of approximately 94% was revealed in clinical trials. Patients can highly benefit from this early detection as appropriate therapy enables preventing or delaying onset of diabetic nephropathy and subsequently end-stage renal disease and dialysis.
Bladder Cancer - DiaPat® BCa-PROteom Test
A cystoscopy is only carried out when blood appears in the urine or frequent and painful urination occurs. The DiaPat® BCa-PROteom Test detects bladder cancer with high reliability. Analysing the urine sample, this non-invasive diagnostic method avoids negative side effects of cystoscopy and is painless and convenient for the patient.
Prostate Cancer – DiaPat® PCa-PROteom Test
A positive PSA test (>4 ng/ml) often results in a prostate biopsy. Inflammations, bleeding or tumour spreading are frequent negative side effects of this procedure. The PCa-PROteom test enables identification of patients not harbouring prostate cancer with high probability that therefore should not undergo prostate biopsy. Analysing the urine proteome, PCa-PROteom test is a non-invasive, riskless and highly reliable diagnostic method. PSA is of limited value in the discrimination of benign and malignant prostate conditions and results in 70% false positive test results. The PCa-PROteom test detects those patients having a positive test result, i.e. tumour is indicated when in fact no cancer is present and consequently can help to reduce the number of biopsy interventions and the related risks.